Linda Powers has pushed the concept of platform from almost the beginning and now it seems the validation through proteomics has made its way to the top regulator in the UK. A little strange that it takes the head of MHRA in the UK to declare this clearly in relationship to a U.S. based company when FDA is supposedly the leader but won’t mention anything like this or can’t create a clear path forward openly for NWBO possibly because of potential big pharma repercussions. Best wishes.
Market Data 
Markets 
AI
